BG
PTCT icon

Bellevue Group’s PTC Therapeutics PTCT Stock Holding History

Bellevue Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133K Sell
1,626
-309
-16% -$22.3K ﹤0.01% 130
2026
Q1 		$132K Sell
1,935
-4,828
-71% -$342K ﹤0.01% 134
2025
Q4 		$514K Buy
6,763
+4,233
+167% +$308K 0.01% 133
2025
Q3 		$155K Sell
2,530
-1,270
-33% -$66.1K ﹤0.01% 134
2025
Q2 		$186K Hold
3,800
– – ﹤0.01% 127
2025
Q1 		$194K Hold
3,800
– – ﹤0.01% 133
2024
Q4 		$172K Buy
+3,800
New +$163K ﹤0.01% 144
2020
Q3 		– Sell
-56,800
Closed -$2.88M – 220
2020
Q2 		$2.88M Sell
56,800
-8,400
-13% -$413K 0.04% 130
2020
Q1 		$2.91M Buy
65,200
+9,100
+16% +$458K 0.06% 121
2019
Q4 		$2.69M Sell
56,100
-25,100
-31% -$1.07M 0.04% 123
2019
Q3 		$2.75M Sell
81,200
-2,300
-3% -$100K 0.05% 123
2019
Q2 		$3.76M Buy
83,500
+48,800
+141% +$1.93M 0.06% 114
2019
Q1 		$1.31M Buy
34,700
+13,000
+60% +$436K 0.07% 119
2018
Q4 		$745K Sell
21,700
-800
-4% -$28.8K 0.05% 126
2018
Q3 		$1.06M Buy
+22,500
New +$931K 0.07% 126
2016
Q2 		– Sell
-35,000
Closed -$225K – 130
2016
Q1 		$225K Buy
+35,000
New +$607K 0.04% 120

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Bellevue Group's PTCT Position: Q2 2026 in Review

Bellevue Group reduced its PTC Therapeutics (PTCT) stake by 16% in Q2 2026, selling an estimated $22.3K and leaving 1,626 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #130.

Bellevue Group first reported a position in PTCT in Q1 2016 and has held it in 16 quarters since. The position peaked at $3.76M in Q2 2019. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Bellevue Group held 1,626 shares of PTC Therapeutics worth $133K as of Q2 2026.
  • Bellevue Group sold 309 PTC Therapeutics shares in Q2 2026, an estimated $22.3K.
  • PTC Therapeutics made up ﹤0.01% of Bellevue Group's portfolio in Q2 2026, its #130 holding.
  • Bellevue Group first reported a position in PTC Therapeutics in Q1 2016 and has held it in 16 quarters since.
  • Bellevue Group's PTC Therapeutics position peaked at $3.76M in Q2 2019.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.